ClinicalTrials.gg
RecruitingNCT07366866Updated Oct 14, 2026

A Study of Safety, Tolerability, PK, and PD of Subcutaneous GenSci136 in Healthy Adults.

A Phase 1 interventional study of GenSci136 and Placebo in Autoimmune Disease, sponsored by Changchun GeneScience Pharmaceutical Co., Ltd.. Recruiting at 1 site in China. Open to participants aged 18 Years to 45 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-10-14.

Sponsored by Changchun GeneScience Pharmaceutical Co., Ltd. · Phase 1, Interventional, and Other

From the registry’s dates

  • Started Mar 2026; still recruiting 8 months later.
Updated Oct 14, 2026Enrollment updatedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
56
Allocation
Randomized
Ages
18 Years to 45 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-18

Among 125 studies in Autoimmune Diseases with a site in China — 72 open to participants now, 78 under way, 7 of them phase 3. Autoimmune Diseases · China.

Planned enrollment
44th of 113
56 · median 30
Started
2026
with 16 others
Phase 1
57 of 125
40 open now
Primary completion
2027-02
later than 29 of 77 live
Registered
109th of 125
by date

Among the 125 studies in Autoimmune Diseases with a site in China, this one is the 44th largest by planned enrollment of the 113 interventional ones that give a count, is one of 17 that started in 2026, is one of 57 in phase 1, reaches primary completion later than 29 of the 77 other live ones, and was the 109th registered.

Autoimmune Diseases

803 studies on the registry are indexed under Autoimmune Diseases; 272 are open to participants now.

Browse Autoimmune Diseases studies →

Open to participants now

72 of the 125 studies in Autoimmune Diseases with a site in China are open now. Recruiting first, the newest first:

66 more — sign in →

All 72 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 195 Autoimmune Diseases studies recruiting now, 90 (46%) set no upper age limit and 79 (41%) stop at 75 or younger; 55 take children under 18; 36 take healthy volunteers.

This study: 18 Years to 45 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 125 studies in Autoimmune Diseases with a site in China, or all of them as a file.
02

Study summary

This study is designed to evaluate the safety, tolerability, PK and PD of GenSci136 in a randomized, double-blind, placebo-controlled trial involving healthy adult participants.

03

Conditions studied

  • Autoimmune Disease

Browse trials for

04

Who can participate

Ages eligible
18 Years to 45 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Male or female, aged 18 to 45 years (both inclusive) at the time of signing form (ICF).
  2. Male body weight ≥ 50 kg or female body weight ≥ 45 kg; between 18-28 kg/m2 (both inclusive) at screening.
  3. Males of reproductive age and females of must agree to take highly effective methods from screening to the end of the study, and have no plans for conception, sperm donation, or egg donation; females of childbearing potential must have a negative pregnancy test at screening/baseline period and are not breastfeeding.
  4. Able to understand the trial procedures, voluntarily participate in the trial, understand and voluntarily sign the ICF, be able to follow all the trial requirements and complete the study.

Exclusion criteria

Exclusion Criteria:

  1. Known to GenSci136 or any of the contained in the GenSci136 formulation, or history of serious hypersensitivity reactions to any drug, compound, food, or other substance, or an allergic constitution.
  2. Presence of tattoo, sunburn, scar or any other factors that may interfere with the assessment of the injection site at the intended injection area.
  3. A history or presence of other significant metabolic, dermatologic, hepatic, renal, hematologic, cardiovascular, gastrointestinal, psychoneurological, respiratory, and/or other major disease that, in the opinion of the investigator, would affect the evaluation of the study.
  4. Any major surgery within 3 months before screening, plan to undergo elective surgery during the study period, or have a history of any surgery that may affect the absorption, distribution, metabolism or excretion of the IMP.
  5. Positive result of alcohol breath test, or drug abuser, or use of soft drugs (such as marijuana) within 3 months prior to screening, or use of hard drugs (such as cocaine and ketamine) within 1 year prior to screening, or positive for drug screening [including but not limited to morphine, ketamine, dimethyldioxyamphetamine, methamphetamine, tetrahydrocannabinol, and cocaine].
  6. Participants judged by the investigator to be ineligible for other reasons.
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

05

Study design

Phase
Phase 1
Primary purpose
Other
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
56 participants (estimated)

Study arms

  • Experimental
    GenSci136

    Single ascending doses of GenSci136 administered subcutaneously (SC).

    Drug: GenSci136

  • Placebo comparator
    Placebo

    Administered SC.

    Drug: Placebo

Interventions

  • DrugGenSci136

    Administered SC.

  • DrugPlacebo

    Administered SC.

06

What researchers measure

Primary outcomes

  1. ● Incidence and severity of treatment-emergent adverse events (TEAEs) ● Incidence and severity of serious adverse events (SAEs)

    Time frame: Day1-Day113

Secondary outcomes

  1. Serum Concentration of free GenSci136/total GenSci136

    Serum concentrations at different time points will be listed and summarized by descriptive statistics.

    Time frame: Day1-Day113

  2. Maximum serum concentration (Cmax)

    PK parameters will be analyzed by non-compartmental analysis with WinNonlin@ version 8.3 or above.

    Time frame: Day1-Day113

  3. Time to maximum serum concentration (Tmax)

    PK parameters will be analyzed by non-compartmental analysis with WinNonlin@ version 8.3 or above.

    Time frame: Day1-Day113

  4. Area under the concentration-time curve from the time zero to last measurable concentration (AUC0-t)

    PK parameters will be analyzed by non-compartmental analysis with WinNonlin@ version 8.3 or above.

    Time frame: Day1-Day113

  5. Area under concentration-time from time zero to infinity (AUC0-inf)

    PK parameters will be analyzed by non-compartmental analysis with WinNonlin@ version 8.3 or above.

    Time frame: Day1-Day113

  6. Terminal elimination half-life (t1/2)

    PK parameters will be analyzed by non-compartmental analysis with WinNonlin@ version 8.3 or above.

    Time frame: Day1-Day113

  7. Clearance (CL/F)

    PK parameters will be analyzed by non-compartmental analysis with WinNonlin@ version 8.3 or above.

    Time frame: Day1-Day113

  8. Apparent volume of distribution (Vd/F)

    PK parameters will be analyzed by non-compartmental analysis with WinNonlin@ version 8.3 or above.

    Time frame: Day1-Day113

  9. ● Changes from baseline in free and total a proliferation inducing ligand (APRIL) levels; ● Changes from baseline in free and total B-cell activating factor (BAFF) levels.

    Time frame: Day1-Day113

  10. Incidence and the time of anti-drug antibody (ADA) positive after GenSci136 administration.

    Time frame: Day1-Day113

07

Study locations

1 of 1 sites recruiting
08

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Mar 2026 (actual). Primary completion is estimated for Feb 2027, 10 months after the start.

Of 69 industry-sponsored phase 1 interventional studies under Autoimmune Diseases, half reached primary completion within 13 months of starting (the median), counting those still running; a quarter within 9 and three quarters within 32. This study's planned 10 months is below that.

Counting every sponsor, half of 95 studies reached it within 23 months; a quarter within 9 and three quarters within 36.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 7, 2026
First posted
Jan 26, 2026
StartActual
Mar 16, 2026
Primary completionEst.
Feb 7, 2027
CompletionEst.
Mar 9, 2027
Last update
Oct 14, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Enrollment
48→56
Oct 14, 2026
Show all 1 update
  1. Oct 14, 2026
    Enrollment 48→56

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

09

Registry details

Key details

Study ID
NCT07366866
Responsible party
Sponsor
First posted
Jan 26, 2026
Start date
Mar 16, 2026
Primary completion
Feb 7, 2027 (estimated)
Completion
Mar 9, 2027 (estimated)
Last update
Oct 14, 2026

Study contacts

Jingsi Li
Contact
lijingsi@genscigroup.com
+86 18301941524

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion